GlassScriptPhysician profile
Divya Naik
NPI 1235711698
$1,377.10
in general payments reported to CMS, 2019-2025
21 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $150 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $316.24 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.01 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $158.62 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $99.41 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $86.93 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $64.32 | 2025 | |
| Gilead Sciences, INC. | $59.57 | 2025 | |
| Pfizer INC. | $54.88 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $43.12 | 2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $40.04 | 2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $34.13 | 2025 | |
| Astellas Pharma US INC | $33.84 | 2025 | Veozah |
| Abbott Laboratories | $31.03 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.98 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $25.79 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $23.07 | 2025 | |
| Dexcom, INC. | $21.80 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $16.69 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $16.60 | 2025 | |
| Insulet Corporation | $15.79 | 2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $15.24 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.